Report Content
Chapter 1 Methodology & Scope
1.1 Industry coverage
1.2 Market scope & definition
1.3 Base estimates & calculations
1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data Sources
1.7.1 Primary
1.7.2 Secondary
1.7.2.1 Paid sources
1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 GI stool testing industry 360º synopsis, 2018 – 2032
2.2 Business trends
2.3 Regional trends
2.4 Product type trends
2.5 Test type trends
2.6 Application trends
2.7 Distribution channel trends
2.8 End-use trends
Chapter 3 GI Stool Testing Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increase in prevalence of Gastrointestinal disorders
3.2.1.2 Technological advancements
3.2.1.3 Rising demand for point-of-care (POC) testing
3.2.1.4 Growing demand for early diagnosis and prevention of GI diseases
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of skilled professionals
3.2.2.2 Stringent regulatory policies
3.3 Growth potential analysis
3.3.1 By product type
3.3.2 By test type
3.3.3 By application
3.3.4 By distribution channel
3.3.5 By end use
3.4 COVID- 19 impact analysis
3.5 Pricing analysis, 2022
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.7 Technology landscape
3.8 Reimbursement scenario
3.9 Future market trends
3.10 Gap analysis
3.11 Porter's analysis
3.12 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Company market share analysis, 2022
4.4 Competitive positioning matrix
4.5 Vendor matrix analysis
4.6 Strategy dashboard
Chapter 5 GI Stool Testing Market Size and Forecast, By Product Type (USD Million & Units)
5.1 Key trends, by product type
5.2 Consumables
5.3 Analyzers
Chapter 6 GI Stool Testing Market Size and Forecast, By Test Type (USD Million)
6.1 Key trends, by test type
6.2 Occult blood test
6.2.1 Guaiac FOB stool test
6.2.2 Immuno FOB agglutination test
6.2.3 Lateral flow immuno FOB test
6.2.4 Immuno FOB ELISA test
6.3 Ova and parasites test
6.4 Bacteria test
6.5 Fecal biomarkers test
6.5.1 Tumor M2-PK stool test
6.5.2 Transferrin assays
6.5.3 Others
6.6 Others
Chapter 7 GI Stool Testing Market Size and Forecast, By Application (USD Million)
7.1 Key trends, by application
7.2 Infection
7.3 Inflammatory bowel disease
7.4 Gastroesophageal reflux disease (GERD)
7.5 Cancer
7.6 Others
Chapter 8 GI Stool Testing Market Size and Forecast, By Distribution Channel (USD Million)
8.1 Key trends, by distribution channel
8.2 Hospital & clinics pharmacies
8.3 Brick & Mortar
8.4 E-commerce
Chapter 9 GI Stool Testing Market Size and Forecast, By End-use (USD Million)
9.1 Key trends, by end-use
9.2 Hospitals & clinics
9.3 Diagnostic centers
9.4 Homecare settings
9.5 Others
Chapter 10 GI Stool Testing Market Size and Forecast, By Region (USD Million & Units)
10.1 Key trends, by region
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Poland
10.3.7 Sweden
10.3.8 The Netherlands
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Thailand
10.4.7 Indonesia
10.4.8 Philippines
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Columbia
10.5.5 Chile
10.5.6 Peru
10.6 MEA
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Israel
10.6.5 Turkey
10.6.6 Iran
Chapter 11 Company Profiles
11.1 Abbott Laboratories
11.2 Alere Inc.
11.3 Beckman Coulter Inc.
11.4 Bio Rad Laboratories
11.5 BioMrieux Inc
11.6 Cardinal Health
11.7 Cenogenics Corporation
11.8 CTK Biotech Inc.
11.9 Danaher Corporation (Beckman Coulter, Inc.)
11.10 DiaSorin S.p.A.
11.11 Epitope Diagnostics Inc.
11.12 Genova Diagnostics
11.13 Meridian Bioscience Inc
11.14 Quest Diagnostics Incorporated
11.15 ScheBo Biotech AG
11.16 Siemens Healthcare
